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OBJECTIVES: To compare cost and utility of asthma treatment with ﬁxed combina-
tions ICSLABA Salmeterol  Fluticasone (SAL/FP maintainance treatment) vs. 
BudesonideFormoterol (BUD/FOR in both maintenance and rescue treatment). 
METHODS: OPTIMA model includes 4 steps-by-step sub-analyses of 1- drugs cost, 
2- cost and utility (quality of life; QoL) with controlled and uncontrolled asthma, 3- 
proportion of controlled and uncontrolled asthma achieved by using comparators, 
4- total cost, saving and utility. In this analysis we used: average drugs prices and 
drugs dosage proportion sold in reimbursement in 2008 from Farmexpert market 
monitoring; number of inhalations per day data was derived from instruction and 
published study (Johansson G. et al. 2006) for SAL/FP and BudesonideFormoterol, 
respectively; QoL and number of resources with controlled and uncontrolled asthma 
was derived from doctoral dissertation of Demko I.V. 2007; resources unit-cost from       
government regulation on 2009 health care insurance program; work-off day cost 
included tax deﬁciency, GDP underproduction and sick pay; frequency of controlled 
asthma from clinical trials (assumption: for BudesonideFormoterol we used maximal 
published % of asthma-control days because of no data on % of asthma-control). 
Core formula of analysis is: cost of drug  % controlled * cost of controlled  % 
uncontrolled * cost of uncontrolled. RESULTS: Average monthly cost of drugs were 
1672 Rub and 1458 Rub (~ a40 EUR and a35) for SAL/FP and BUD/FOR, respec-
tively. Cost and QoL and were 320 Rub (~ a8) and 0.75 in controlled and 62,753 
Rub (a1400) and 0.49 in uncontrolled asthma. Drugs allow to achieve asthma-control 
in 75% (GOAL study) and 47.4% (see assumption), respectively. Total cost were 
35,991 Rub and 50,654 Rub; utility were 0.69 and 0.613 for SAL/FP and BUD/FOR, 
respectively. CONCLUSIONS: Total cost in SAL/FP arm is lower than in BUD/FOR, 
but utility is higher. Therefore, SAL/FP is the dominating alternative.
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OBJECTIVES: To show the economic consequences of implementing reimbursement 
for pharmacological smoking cessation, i.e. varenicline, in Denmark compared with 
future disease events avoided and corresponding savings in the health care sector and 
the society due to reduced smoking prevalence. METHODS: A costing template 
developed by the National Institute for Health and Clinical Excellence in UK for the 
implementation of varenicline in smoking cessation in the UK (http://guidance.nice.
org.uk/TA123/CostTemplate/xls/English) was adjusted and applied for Denmark 
using Danish data on smokers, costs of pharmacological smoking cessation, costs of 
disease events, etc. and Danish reimbursement rules. RESULTS: The public health 
insurance costs in Denmark for reimbursing a quit-motivated smoker 12 weeks of 
prescribed varenicline will amount to 949–1,920 DKK (1 Euro  7.45 DKK) with 
co-payment being lower for chronically ill persons. Assuming reimbursing 40,000 
smokers will then be at a cost for the national health insurance between 38–77 million 
DKK. However, the beneﬁt will be 9,000 abstinent persons, thus preventing respec-
tively 2110, 3383 and 5214 disease events (50% COPD) after 2, 10 and 20 years, 
respectively. Accordingly after 2 years, the health care sector savings due to an avoided 
ﬁrst acute hospital contact (DRG-charges for each disease) amount to 47 mill. DKK 
or 281 mill. DKK for the society, when health care savings after the ﬁrst acute contact 
and production lost are included. At 20 years health care sector savings rise to 141 
million DKK (or 846 million DKK in societal savings) due to 9000 abstinent persons. 
CONCLUSIONS: The study shows that break-even between higher health insurance 
costs (reimbursement of prescribed varenicline) and costs saved due to avoidance of 
the ﬁrst acute hospital contact will for persons with a low reimbursement rate appear 
less than 2 years after initiation of smoking cessation. Varenicline is reimbursed in 
Sweden, UK, Ireland and Belgium, but not in Denmark.
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Nearly 300,000 Danes have undetected chronic obstructive lung disease (COPD) 
with reduced quality of life (QoL) and high societal costs. The earlier COPD can be 
detected the higher is the chance that progression of COPD severity stages can be 
curbed. OBJECTIVES: Following the recommendations by the Danish National 
Board of Health to analyse the economic consequences for the health care sector and 
society of an early detection of COPD in patients visiting their general practitioner 
(GP). METHODS: In the project covering 10% of the Danish GPs (n  335) patients 
fulﬁlling a number of criteria (35 years, smoking/tobacco exposure, no previous 
COPD, q1 lung symptom, i.e. cough, dyspnea, wheezing, phlegm) were offered spi-
rometry. Airway obstruction was deﬁned as FEV1/FVC 70% with COPD severity 
levels according to GOLD. A literature review in Medline identiﬁed annual costs of 
COPD severity stages. Saved costs of early detection were calculated as the cost dif-
ference between COPD stages. The results were extrapolated to a Danish setting. 
RESULTS: Of the 3,099 patients (mean age 57 years) included 35% were screened 
as being airway obstructive (29% mild, 51% moderate, 18% severe, 2% very severe). 
In terms of COPD costs all published studies reviewed showed increasing costs with 
increased disease severity. Screening 25% of the undetected COPD patients in 
Denmark—assuming the same distribution on severity stages as found in the study— 
a77–213 million can potentially be saved annually in the health care sector, if pro-
gression to more severe COPD stages is avoided. With a 100% screening success 
annual savings increase to a309–894 million. Adding production lost will increase 
this further. CONCLUSIONS: Early detection of COPD at the GP-level is cost-
 effective, even when the screening costs are subtracted. Furthermore, the patients 
QoL will increase. Early detection of COPD ought to be a responsibility for every GP 
in the future.
PRS11
ANALYSIS OF ASTHMA-RELATED OUTCOMES AND COSTS FOR 
PERSISTENT ASTHMA PATIENTS TREATED WITH BECLOMETHASONE 
DIPROPIONATE HFA OR BUDESONIDE INHALATION POWDER
Lage MJ1, Gross G2, Brewster C3, Spalitto A3
1HealthMetrics Outcomes Research, LLC, Groton, CT, USA, 2Dallas Allergy and Asthma 
Center, Dallas, TX, USA, 3Teva Respiratory, Horsham, PA, USA
OBJECTIVES: Examine outcomes and costs for persistent asthma patients who initi-
ated therapy with beclomethasone dipropionate HFA (BDP-HFA—e.g., QVAR®) or 
budesonide inhalation powder (BUD—e.g., Pulmicort®). METHODS: MedStat’s 
Commercial Claims and Encounter Database (July 1, 2002—June 30, 2007) was uti-
lized. Patient who initiated therapy with BDP-HFA or BUD (ﬁrst use  index date) 
and met the following criteria: a) no receipt of other study medication in the 1 year 
post-period; b) persistent asthma in the 1 year pre—period; c) age 5–64; d) no diag-
nosis of COPD; and e) continuous insurance coverage from 1 year pre through 1 year 
post-period were included (N  8,418). Logisitc regressions examined the probability 
of an asthma-related ER visit or hospitalization while general linear modesl with a 
log link were used to examine the association between receipt of BDP-HFA or BUD 
on asthma-related annual total costs and cost components. RESULTS: Receipt of 
BDP-HFA, compared to BUD, was associated with a 37% reduction in the odds of 
an asthma-related ER visit (OR  0.628; 95% CI 0.506–0.780) and a 35% reduction 
in the odds of an asthma-related hospitalization (OR  0.646; 95% CI 0.501–0.832). 
Asthma related total annual costs were signiﬁcantly lower for the BDP-HFA cohort 
compared to the BUD cohort ($1142 vs. $2078; P  0.0001) as were asthma related 
component costs of inpatient costs ($228 vs. $615; P  0.0001), outpatient costs ($264 
vs. $427; P  0.0001), ER costs ($61 vs. $142; P  0.0001), and drug costs ($648 vs. 
$1167, P  0.0001). CONCLUSIONS: Results indicate that for persistent asthma 
patients receipt of BDP-HFA, compared to receipt of BUD is associated with a 
decreased probability of asthma-related hospitalization or ER visits and lower asthma-
related costs.
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OBJECTIVES: To estimate direct and indirect costs and quality of life (QoL) of 
patients with COPD exacerbation in comparison with costs and QoL of patients with 
similar COPD severity (GOLD criteria) but without exacerbation. METHODS: A 
total of 90 in- and outpatients with COPD (grade II–IV) exacerbation (EXA-group) 
were assessed retrospectively (3 month prior to exacerbation) and prospectively (3 
month after exacerbation). A control (CO-group) of 90 patients with the same grade 
distribution but in stable health during past 3 months was assessed retrospectively 
(past 3 months). Direct costs were hospitalization, outpatient visits, laboratory tests, 
imaging, medication and rehabilitation. Indirect costs included short and long term 
disability payments. All costs were converted to a period of 180 days; health care costs 
used 2008 prices from the payer’s perspective. At inclusion day (in both groups) and 
at ﬁnal visit in the EXA-group a validated Czech translation of the EQ5D was com-
pleted. RESULTS: Both groups were comparable at baseline in terms of age, gender, 
duration of COPD. Mean 6-months costs were signiﬁcantly higher, a3796 vs. 
a1540(1a  26CZK), in the EXA-group (p  0.001). Direct costs accounted for 86 % 
in the EXA-group and 78 % in the CO-group. Costs for exacerbation management 
(hospitalization and/or outpatient treatment) and medication represented major cost-
drivers in the EXA-group. In the CO-group medication represented 52 % of direct 
costs. EQ5D utilities in the CO-group and in the EXA-group at ﬁnal visit were com-
parable (0.566 EXA-group vs. 0.582 CO-group; NS). EXA-group utilities at inclusion 
were signiﬁcantly lower compared to ﬁnal measurement (0.377 EXA-entry v.s. 0.566 
EXA-ﬁnal; p  0.001), reﬂecting the quality of life impairment during COPD exacerba-
tion. CONCLUSIONS: The BURDEN study conﬁrmed for the Czech Republic a 
considerable economic burden of COPD exacerbations. It also showed severe impair-
ment of QoL. Results are in accordance with international literature.
